Anti-Mouse CD69 Antibody (CD69.2.2)
Anti-Mouse CD69 Antibody (CD69.2.2) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD69. Anti-Mouse CD69 Antibody (CD69.2.2) causes CD69 to be internalized but does not deplete CD69+ cells. Anti-Mouse CD69 Antibody (CD69.2.2) can be used for the researches of cancer, infection, inflammation and immunology, such as RMA-S tumor, arthritis and vaccinia virus (VACV) infection.
For research use only. We do not sell to patients.
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mouse IgG1 kappa
Mouse
CD69
Anti-Mouse CD69 Antibody (CD69.2.2) (10 μg/mL, 1 h) is readily internalized at 37°C in CD69+ cells[1].
Anti-Mouse CD69 Antibody (CD69.2.2) (10 μg/mL, 18 h) increases cytotoxicity of NK cells in splenocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse CD69 Antibody (CD69.2.2) (500 μg, i.p., at days 1 and 5) reduces tumor metastasis and prolongs survival in RM-1 tumor mice models[1].
Anti-Mouse CD69 Antibody (CD69.2.2) (200 μg, i.p., a single dose) consistently and significantly increases NK-dependent cytotoxic activity in RMA-S/RM-1/YAC-1 tumor mice models[1].
Anti-Mouse CD69 Antibody (CD69.2.2) (300 μg, i.p., at days 1 and 5) downregulates CD 69 expression and does not affect disease severity in collagen antibody-induced arthritis mice models[2].
Anti-Mouse CD69 Antibody (CD69.2.2) (500 μg, i.v., 24 h before infection) enhances the innate immune response in vaccinia virus (VACV)-infected mice models[3].
Anti-Mouse CD69 Antibody (CD69.2.2) (200 μg, i.v., twice a week) shows anti-infection in vaccinia virus (VACV)-infected Rag2-/- mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:RM-1 tumor mice models[1]
-
Dosage:500 μg
-
Administration:Intraperitoneally injection, at days 1 and 5
-
Result:Drastically reduced tumor metastasis.
Increased survival rate of mice.
-
Animal Model:Vaccinia virus (VACV)-infected mice models[3]
-
Dosage:500 μg
-
Administration:Intraperitoneally injection, 24 h before infection
-
Result:Showed slightly lower ovarian viral titers.
Increased the numbers of TNF-α-producing NK, CD8+ T, and CD4+ T cells and IFN-γ-producing NK and CD4+ T cells.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo down-regulation of CD69 expression; Functional assays
Chemical Information
-
Molecular Weight 150 kDa
-
SMILES
[Anti-Mouse CD69 Antibody (CD69.2.2)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Esplugues E, et al. Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. Blood. 2005 Jun 1;105(11):4399-406. [Content Brief]
[2]. Lamana A, et al. The role of CD69 in acute neutrophil-mediated inflammation. Eur J Immunol. 2006 Oct;36(10):2632-8. [Content Brief]
[3]. Notario L, et al. CD69 Targeting Enhances Anti-vaccinia Virus Immunity. J Virol. 2019 Sep 12;93(19):e00553-19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD69 Antibody (CD69.2.2) Related Classifications
HY-P990265 Related Classifications
Powered by Bioz